NR1H4 and primary biliary cholangitis: In contrast, however, to AIH and PSC, the treatment paradigm for PBC is based on bile acids, such as ursodeoxycholic acid and obeticholic acid (OCA), a Farnesoid-X-Receptor (FXR) agonist, and Peroxisome Proliferator-Activated Receptor (PPAR)s ligands [2], although these agents have no effects on AIH, where the cornerstone therapy is the immunosuppression, and no licensed drug have been proven effective in slowing disease progression in PSC [3,4].